泰福-KY News Releases

【Tanvex-KY】Subsidiary Tanvex BioPharma USA, Inc. Receives Complete Response Letter (CRL) from U.S. FDA Regarding Biosimilar Drug TX05 (Herceptin Biosimilar) Due to Inspection Issues at Downstream Fill-Finish Facility

Tanvex BioPharma USA, Inc., a 100%-owned subsidiary of Tanvex-KY, has received a Complete Response L… · 2026-06-24

[TF-KY] Subsidiary Taiwan TF Biotech Announces Capital Reduction to Offset Losses and Creditor Notification

Taiwan TF Biotech has resolved to carry out a 99.4% capital reduction to improve its financial struc… · 2026-06-22

[Tanvex-KY] February 2026 Revenue Reaches 0.23 Billion (YoY +218.7%)

Tanvex-KY has announced its impressive revenue report for February 2026. The company's revenue for t… · 2026-02-01

[Tanvex BioPharma (6541)] May 2026 Revenue Reaches NT$36 Million (YoY +208.2%)

Tanvex BioPharma, Inc. (6541), operating in the biotechnology and healthcare sector, reported its mo… · 2026-05-01

Tai-Fu KY appoints independent director Zeng Zhiyang

Zeng Zhiyang appointed independent director on 2026-06-04, holding 0 shares. · 2026-06-04

[UltraGen-KY] Announcement Regarding Board Resolution to Waive Non-Compete Restrictions for Directors

UltraGen-KY announced that the Annual General Meeting held on June 4, 2026, approved the waiver of n… · 2026-06-04

Tai-Fu KY Announces Key Resolutions from 115th Meeting

Approved loss offset, financial reports, director election, asset/guarantee revisions, private place… · 2026-06-04

Tai Fu-KY Announces Audit Committee Change

Tai Fu-KY appoints Zeng Zhiyang, chair of Wei Cai Pharma, to audit committee on 115/06/04. · 2026-06-04

[TaiFu-KY] March 2026 Monthly Revenue Reaches NT$0.92 Billion (YoY +134.7%)

TaiFu-KY announced its monthly revenue for March 2026 reached NT$0.92 billion, marking a substantial… · 2026-03-01

[TAIFU-KY] Announces Change of Internal Audit Supervisor

TAIFU-KY announces a change in its Internal Audit Supervisor. Ms. Hong Yu-mei will be succeeded by M… · 2026-05-12

【TaiFu-KY】Announcement of the Board of Directors' approval of the 2026 First Quarter Consolidated Financial Report

TaiFu-KY announced on May 12, 2026, that its Board of Directors approved the first-quarter consolida… · 2026-05-12

[Taifou-KY] April 2026 Revenue 87 Million (YoY +914.9%)

Taifou-KY announced its April 2026 monthly revenue was 87 million TWD, a dramatic increase of +914.9… · 2026-04-01

【TaiFu-KY】Announcement of Board Meeting Date for Q1 2026 Consolidated Financial Report

TaiFu-KY announced that its board meeting to discuss the Q1 2026 consolidated financial report will … · 2026-05-04

[Tanvex-KY] Announcement of Endorsement/Guarantee Pursuant to Article 25, Paragraph 1, Item 4 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

Tanvex-KY announced the provision of an endorsement/guarantee of NTD 479.9 million to its 100% subsi… · 2026-04-22

[Tanvex-KY] Announcement of the Board's resolution to issue common shares and/or domestic/overseas unsecured convertible bonds via private placement

The Board of Tanvex-KY approved a private placement of common shares or convertible bonds, targeting… · 2026-04-22

[Tanvex-KY] Announcement of the board's resolution to convene the 2026 Annual Shareholders' Meeting (with added agenda items)

Tanvex BioPharma's board resolved to hold its AGM on June 4, 2026. Key agenda items include a defici… · 2026-04-22

[Tanvex-KY] Announcement on behalf of important subsidiary Taiwan Tanvex Biochemical Inc. regarding the board's resolution not to distribute dividends

Tanvex BioPharma announced that the board of its key subsidiary, Taiwan Tanvex Biochemical, resolved… · 2026-04-22